文献速递消化内镜

新型硫酸盐片剂与PEG-抗坏血酸肠道准备的安全性和有效性比较

A Safety and Efficacy Comparison of a New Sulfate-Based Tablet Bowel Preparation Versus a PEG and Ascorbate Comparator in Adult Subjects Undergoing Colonoscopy.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

结果显示OST清洁成功率92%,非劣效于PEG-EA的89%,且OST在整体和近端结肠达到优秀准备的比例显著更高。两种准备方案耐受性良好,严重预期胃肠道症状发生率均低于5%,OST未报告严重不良事件。

要点

  • OST肠道准备清洁成功率达92%,非劣效于PEG-EA的89%。
  • OST在整体和近端结肠达到优秀准备的比例显著高于PEG-EA。
  • 两种准备方案严重预期胃肠道症状发生率均低于5%,安全性相当。

核心结论

  • 口服硫酸盐片(OST)在结肠镜检查肠道准备中非劣效于PEG-EA,且整体和近端结肠优秀准备率显著更高。

主要发现

  • OST清洁成功率92%,PEG-EA为89%,OST非劣效于PEG-EA。
  • OST在整体和近端结肠达到优秀准备的比例显著高于PEG-EA。
  • 两种准备方案严重预期胃肠道症状发生率均低于5%,实验室参数无临床显著差异,OST未报告严重不良事件。

关键数值与推荐

  • 清洁效果采用4分制评估(优秀、良好、一般、差),良好或优秀视为成功。
  • OST方案:检查前晚服用12片,次日晨再服12片,共24片;每剂12片配16盎司水,另额外饮水32盎司。
  • PEG-EA按批准标签使用:晚间1升准备液加16盎司水,次晨重复。

临床怎么用

  • OST可作为结肠镜检查肠道准备的一种有效且耐受性良好的替代方案,尤其适用于希望避免大量液体摄入的患者。

局限性

  • 研究为单盲设计,患者对准备方案无法设盲,可能影响症状报告的主观性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A new tablet-based bowel prep for colonoscopy has been developed containing poorly absorbed sulfate salts which act to retain water within the intestinal lumen resulting in a copious diarrhea, thereby cleansing the bowel. This study evaluated the safety and efficacy of these oral sulfate tablets (OST) compared with a US FDA-approved bowel prep solution containing PEG3350, electrolytes, and ascorbate (polyethylene glycol and ascorbate [PEG-EA]). METHODS: Five hundred fifteen adult patients (mean 57y) were enrolled in this single-blind, multicenter, noninferiority study. Subjects were assigned either PEG-EA or OST to be administered in a split-dose regimen starting the evening before colonoscopy. PEG-EA was taken according to its approved labeling (1 L of prep solution with 16 oz. of additional water) in the evening and again in the morning. OST patients took a total of 24 tablets. OST patients were administered 12 tablets in the evening, and the following morning. Patients consumed 16 ounces of water with each dose of 12 tablets and drank an additional 32 oz. of water with each dose. Colonoscopies were performed by blinded investigators. Cleansing efficacy was evaluated globally and segmentally using a 4-point scale (Excellent-no more than small bits of feces/fluid which can be suctioned easily; achieves clear visualization of the entire colonic mucosa. Good-feces and fluid requiring washing and suctioning, but still achieves clear visualization of the entire colonic mucosa. Fair-enough feces even after washing and suctioning to prevent clear visualization of the entire colonic mucosa. Poor-large amounts of fecal residue and additional bowel preparation required). Scores of Good or Excellent were considered to be a success. Safety was assessed by spontaneously reported adverse events, solicited ratings of expected prep symptoms, and laboratory testing. RESULTS: A high rate of cleansing success was seen with OST (92%), which was noninferior to PEG-EA (89%). Only a small proportion of subjects rated their expected gastrointestinal symptoms as severe (<5% for both preps). No clinically significant differences were seen between preps for chemistry and hematology parameters. No serious adverse experiences were reported with OST. DISCUSSION: Sulfate tablets achieved a high level of cleansing in the study, comparable with US FDA-approved preps. OST was noninferior to PEG-EA in this study and achieved significantly more Excellent preps overall and in the proximal colon. The OST prep was well-tolerated, with a similar rate of spontaneously reported adverse experiences to PEG-EA and a low rate of severe expected gastrointestinal symptoms.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Di Palma JA, Bhandari R, Cleveland MV, et al. A Safety and Efficacy Comparison of a New Sulfate-Based Tablet Bowel Preparation Versus a PEG and Ascorbate Comparator in Adult Subjects Undergoing Colonoscopy. Am J Gastroenterol. 2021. PMID: 33165006. doi:10.14309/ajg.0000000000001020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。